BridgeBio Pharma BBIO Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in other liabilities?
- BridgeBio Pharma (BBIO) reported change in other liabilities of $4.62M in Q1 2026.
- How has BridgeBio Pharma's change in other liabilities changed year-over-year?
- BridgeBio Pharma's change in other liabilities increased by 56.8% year-over-year, from $2.95M to $4.62M.
- What is the long-term trend for BridgeBio Pharma's change in other liabilities?
- Over 2 years (2023 to 2025), BridgeBio Pharma's change in other liabilities has grown at a 370.4% compound annual growth rate (CAGR), from $3.52M to $77.81M.
- What does change in other liabilities mean?
- The net change in miscellaneous obligations not categorized as accounts payable or debt.
- How do you interpret change in other liabilities?
- An increase provides a cash flow benefit, while a decrease represents a cash outflow as obligations are settled.
- How does change in other liabilities compare across companies?
- Varies significantly by industry; biotech firms often see fluctuations due to clinical trial accruals.